Heidelberg Pharma AG Logo

Heidelberg Pharma AG

Develops cancer therapies using its proprietary ATAC Antibody-Drug Conjugate technology.

HPHA | F

Overview

Corporate Details

ISIN(s):
DE000A11QVV0
LEI:
391200E09XYBYITR1W32
Country:
Germany
Address:
Gregor-Mendel-Str. 22, 68526 Ladenburg
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Heidelberg Pharma AG is a biopharmaceutical company specializing in the research and development of innovative cancer therapies. The company's core focus is on its proprietary Antibody-Drug Conjugate (ADC) technology platforms. A key asset is its patented ATAC® (Antibody Targeted Amanitin Conjugate) technology, which utilizes the unique biological mode of action of the toxin Amanitin. This approach aims to develop highly effective treatments for various malignant hematological and solid tumors, with the potential to overcome drug resistance and eliminate quiescent tumor cells. The company advances its own pipeline of clinical candidates while also collaborating with pharmaceutical partners.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 15:58
Earnings Release
Heidelberg Pharma AG Announces Updated Guidance
English 10.7 KB
2025-09-25 10:51
Regulatory News Service
Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC…
English 13.5 KB
2025-09-04 09:46
Regulatory News Service
Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to…
English 12.2 KB
2025-08-28 03:50
Regulatory News Service
Heidelberg Pharmas Partner Telix Pharmaceuticals Gives Regulatory Update for it…
English 11.8 KB
2025-07-31 17:14
Declaration of Voting Results & Voting Rights Announcements
Release according to Article 41 of the WpHG [the German Securities Trading Act]…
English 4.5 KB
2025-07-31 00:00
Registration Form
Datum:31.07.2025
German 9.2 KB
2025-07-31 00:00
Post-Annual General Meeting Information
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.12.2023 bis zum 30.11.2024
German 5.9 KB
2025-07-24 14:24
Director's Dealing
Heidelberg Pharma AG: Prof. Dr. Andreas Pahl, Acquisition of 90,000 shares thro…
English 6.3 KB
2025-07-23 00:00
Related Party Transaction
Datum:23.07.2025
German 8.1 KB
2025-07-10 07:03
Earnings Release
Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Bu…
English 26.9 KB
2025-07-10 00:00
Interim Report
Half-yearly financial report 2024/2025
English 2.1 MB
2025-05-27 08:07
Regulatory News Service
Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-ba…
English 12.1 KB
2025-05-16 14:31
Post-Annual General Meeting Information
Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting…
English 12.5 KB
2025-05-14 18:40
Regulatory News Service
Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candi…
English 14.1 KB
2025-04-24 07:16
Quarterly Report
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial …
English 27.8 KB

Automate Your Workflow. Get a real-time feed of all Heidelberg Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Heidelberg Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-01-31 Pahl, Prof. Dr. Andreas Board Other None N/A
2023-12-18 Pahl, Prof. Dr. Andreas Board Buy None 10,130.00 EUR
2022-10-13 4H invest GmbH Close relation Other None 993,666.24 EUR
2022-10-13 Bohlini invest GmbH Close relation Other None 964,061.56 EUR
2022-10-13 MH-LT-Investments GmbH Close relation Other None 506,241.96 EUR
2022-10-13 Schneiders, Michael Board Buy None 13,088.40 EUR
2022-10-13 Schneiders, Michael Board Buy None 4,895.60 EUR
2022-09-07 Plate, Achim Board Buy None 30,869.92 EUR
2022-09-06 Kudlek, Dr. Birgit Supervisory board Other None 7,496.16 EUR
2022-03-22 4H invest GmbH Close relation Other None N/A

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.